Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OsteoporeASX:OSX +25.00% 3-Year EBITDA Growth Rate is 43.90% as of Dec. 2025, which is 67% above its 10-year median of 26.35. The stock has 7 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Osteopore ranks better than 85.69% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 43.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Osteopore was 43.90% per year. The lowest was -19.50% per year. And the median was 26.35% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Osteopore 3-Year EBITDA Growth Rate Related Terms
ASX:OSX vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Osteopore's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Osteopore 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Osteopore's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 43.90% mean?
Osteopore (ASX:OSX) has a 3-Year EBITDA Growth Rate of 43.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Osteopore and its competitors. This is 67% above median its historical median of 26.35. According to the industry distribution chart, Osteopore ranks #99 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 14.3%.
Is Osteopore's 3-Year EBITDA Growth Rate too high?
Osteopore's current 3-Year EBITDA Growth Rate of 43.90% is 67% above median its 10-year median of 26.35. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.65. Osteopore's value of 43.90% is 473.9% above this industry median. Based on the distribution chart, Osteopore ranks #99 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Osteopore's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Osteopore ranks #99 out of 692 companies for 3-Year EBITDA Growth Rate. This places Osteopore in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.65. Osteopore's value of 43.90% is 473.9% above this benchmark. While the company's 10-year median is 26.35 vs. the industry median of 7.65, Osteopore has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.65, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Osteopore's current 3-Year EBITDA Growth Rate of 43.90% is 473.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Osteopore and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Osteopore's current 3-Year EBITDA Growth Rate is 43.90%, which is 67% above median its own 10-year median of 26.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 75% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 43.90%, which is 67% above median its 10-year median of 26.35 and 473.9% above the Medical Devices & Instruments industry median of 7.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current 3-Year EBITDA Growth Rate is 43.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSX has been successfully added to your 
